Literature DB >> 12192562

Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines.

Ulrike Seitz1, Martin Wagner, Bernd Neumaier, Edgar Wawra, Gerhard Glatting, Gerhard Leder, Roland M Schmid, Sven N Reske.   

Abstract

Here we report the expression of major pyrimidine metabolising enzymes in pancreatic cancer cell lines, chronic pancreatitis tissue and human pancreatic cancer and the in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT). The expression of pyrimidine metabolising enzymes was evaluated with real-time PCR, Western blot and immunostaining. Thymidine kinase 1 (TK-1) activity was measured with a fluorocytometric assay. The cellular uptake and intracellular metabolism of [(18)F]FLT were evaluated in pancreatic lobules and in transformed cancer cell lines. TK-1 and thymidine synthetase mRNA were increased in six pancreatic cancer cell lines, while mRNA levels of thymidine kinase 2 and deoxycytidine kinase were down-regulated. High TK-1 activity was confirmed in all cell lines. Furthermore, TK-1 was overexpressed in human pancreatic cancer as compared with normal pancreatic tissue and samples from patients with chronic pancreatitis. The cellular uptake of [(18)F]FLT was 18.4%+/-3.6% and 5.2%+/-1.4% of the applied radioactivity after 240 min in SW-979 and BxPc-3 cells, respectively, while uptake of [(18)F]fluorodeoxyglucose ([(18)F]FDG) was only 0.6%+/-0.04% (SW-979) and 0.3%+/-0.13% (BxPc-3) after 240 min of incubation. In contrast, cellular uptake of [(18)F]FLT in isolated pancreatic lobules and growth-arrested HT1080 cells was lower as compared with the uptake of [(18)F]FDG and with the malignant pancreatic cancer cell lines. HPLC analysis of the perchloric acid-soluble cell fraction demonstrated the phosphorylation of [(18)F]FLT to the respective monophosphate in both cell lines. Furthermore, 0.8%+/-0.12% (BxPc-3) and 1.3%+/-0.38% (SW-979) of the applied radioactivity was detected in the perchloric acid-insoluble cell fraction, indicating the incorporation of [(18)F]FLT into the DNA. Our results demonstrate the cellular uptake, intracellular trapping and incorporation into the DNA of [(18)F]FLT in pancreatic cancer cells in vitro. TK-1, as the rate-limiting enzyme of [(18)F]FLT metabolism, is overexpressed in pancreatic cancer cell lines and in human pancreatic cancer. Thus, we propose [(18)F]FLT as a promising tracer for positron emission tomography that might overcome current limitations in the diagnosis of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12192562     DOI: 10.1007/s00259-002-0851-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  29 in total

1.  Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.

Authors:  Sarah R Mudd; Kimberley D Holich; Martin J Voorbach; Todd B Cole; David R Reuter; Paul Tapang; Gail Bukofzer; Arunava Chakravartty; Cherrie K Donawho; Joann P Palma; Gerard B Fox; Mark Day; Yanping Luo
Journal:  Mol Imaging Biol       Date:  2012-10       Impact factor: 3.488

2.  A novel in vitro assay to assess phosphorylation of 3'-[(18)F]fluoro-3'-deoxythymidine.

Authors:  Ning Guo; Jingping Xie; H Charles Manning; Natasha G Deane; M Sib Ansari; Robert J Coffey; John Gore; Ronald R Price; Ronald M Baldwin; J Oliver McIntyre
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

Review 3.  Development of radiotracers for oncology--the interface with pharmacology.

Authors:  Rohini Sharma; Eric Aboagye
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

4.  Fluorine-18-Labeled Thymidine Positron Emission Tomography (FLT-PET) as an Index of Cell Proliferation after Pharmacological Ascorbate-Based Therapy.

Authors:  John A Cieslak; Zita A Sibenaller; Susan A Walsh; Laura L Boles Ponto; Juan Du; John J Sunderland; Joseph J Cullen
Journal:  Radiat Res       Date:  2015-12-31       Impact factor: 2.841

Review 5.  [18F]FLT-PET in oncology: current status and opportunities.

Authors:  Lukas B Been; Albert J H Suurmeijer; David C P Cobben; Pieter L Jager; Harald J Hoekstra; Philip H Elsinga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12       Impact factor: 9.236

6.  Assessment of therapy response in malignant tumours with 18F-fluorothymidine.

Authors:  Rakesh Kumar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09       Impact factor: 9.236

7.  The role of 18F-FLT in cancer imaging: does it really reflect proliferation?

Authors:  Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

8.  [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors.

Authors:  Seung Jin Choi; Jae Seung Kim; Jeong Hoon Kim; Seung Jun Oh; Jeong Gyo Lee; Chang Jin Kim; Young Shin Ra; Jeong Seok Yeo; Jin Sook Ryu; Dae Hyuk Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-02-15       Impact factor: 9.236

9.  Evaluation of 3'-deoxy-3'-[18F]-fluorothymidine (18F-FLT) kinetics correlated with thymidine kinase-1 expression and cell proliferation in newly diagnosed gliomas.

Authors:  Aya Shinomiya; Nobuyuki Kawai; Masaki Okada; Keisuke Miyake; Takehiro Nakamura; Yoshio Kushida; Reiji Haba; Nobuyuki Kudomi; Yuka Yamamoto; Masaaki Tokuda; Takashi Tamiya
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-15       Impact factor: 9.236

Review 10.  Fluorinated tracers for imaging cancer with positron emission tomography.

Authors:  Olivier Couturier; André Luxen; Jean-François Chatal; Jean-Philippe Vuillez; Pierre Rigo; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-07-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.